Reading , RG2 6UU
The aim of this meeting is to provide a relaxed environment for career young statisticians
where they can present and discuss various statistical topics and interact/network with other statisticians in similar positions to themselves. The PSI conference and similar events can be daunting for some attendees both in terms of who is in the audience and also in being happy that what they present is deemed new and original. For this one day meeting the audience will be peers with similar levels of experience and will include content of interest to career young statisticians. In addition to presentations from fellow statisticians there will be a soft skills workshop on explaining statistics to non‐statisticians and ample opportunity to connect with colleagues across the industry.
CLICK HERE TO VIEW THE FLYER
Registration Costs:
| PSI Members | £25 + VAT |
| Non-Members | £95 + VAT |
The agenda for the meeting can be found below:
| 9.30 -9.55 | Registration |
| 9.55 – 10.00 | Welcome and Introduction |
| 10.00 – 11.00 | One label with different interpretations…Statistical lead, what does it really mean? |
|
| Charlotte Eden and Lucie Tesarova, QuintilesIMS |
| 11.00 – 11.20 | Break |
| 11.20 – 11.50 | Exploring recent developments in the MAMS methodology for designing an adaptive trial |
|
| Julia Abery, University of Reading |
| 11.50 – 12.20 | Seamless Study Designs & Real-time Data Capture Using Electronic Devices |
|
| Rhian Jacob, Roche |
| 12.20 – 13.20 | Lunch |
| 13.20 – 14:20 | Training session: Explaining statistics to non-statisticians |
|
| James Matcham, AstraZeneca / PSI Training Committee |
| 14.20 – 14.40 | Break |
| 14.40 – 15.10 | Introduction to Pharmacokinetics |
|
| Laura Cope, Quanticate |
| 15.10 – 15.40 | AdePro – A new Perspective on Safety Profiles |
|
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG |
| 15.40 – 16.00 | Break |
| 16.00 – 16.30 | Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes |
|
| Nirav Ratia, GSK |
| 16.30 | Close |
One label with different interpretations…Statistical lead, what does it really mean?
| Charlotte Eden and Lucie Tesarova, QuintilesIMS | Exploring the role of the Statistical lead from different perspectives. Focusing on life in a CRO to experiences in Pharma with audience participation to discuss how we work on some key factors throughout the life of a study. |
Exploring recent developments in the MAMS methodology for designing an adaptive trial
| Julia Abery, University of Reading | Multi-arm adaptive trials allow several new drugs to be assessed simultaneously, potentially giving improved efficiency over conventionally designed trials. In such a trial, data accumulating during the study are utilised to inform decisions about how the remainder of the trial should be conducted. Several different methodological approaches have been developed for multi-arm adaptive trials and a number of studies have compared the performance of different subsets of these proposed methods. The comparisons have not, however, considered the so-called MAMS approach, since methodology for the latter did not incorporate strong control of the family-wise error rate (FWER). Recently, the MAMS approach has been extended such that strong control of the FWER can be guaranteed. Furthermore, an automated process has been developed which can produce efficient designs for trials with any number of stages and treatment arms.Since MAMS is relatively easy to understand and implement, we set out to explore these developments and to compare MAMS to other well established methods.We show how MAMS compares favourably with the more established combination method for some scenarios and explore how use of a novel selection rule may offer a further option within MAMS methodology. |
Seamless Study Designs & Real-time Data Capture Using Electronic Devices
| Rhian Jacob, Roche | Developing a new drug in a highly competitive environment necessitates a fast to market approach. This talk looks at the ongoing '944' trial, a multiple cohort seamless phase II/III study. Key study endpoints are captured using electronic devices, providing high volume of data in real-time. This talk describes the opportunities and challenges for a statistician leading a phase II readout within a phase III framework, with discussion on novel data capture methods; is the industry ready to handle device data? |
Training session: Explaining statistics to non-statisticians
| James Matcham, AstraZeneca / PSI Training Committee |
|
Introduction to Pharmacokinetics
| Laura Cope, Quanticate | Pharmacokinetics is the study of the effect of the body on the drug. The pharmacokinetic profile maps the concentration of the drug in the body over time tracking how the drug is absorbed, distributed, metabolised and excreted by individuals. Drug concentration is linked to both efficacy and safety and hence pharmacokinetic studies form the basis of much earlier phase clinical trials. Pharmacokinetic profiles are often described using summary measures such as the area under the curve (AUC) and the maximum concentration (Cmax) but how are these parameters derived? What models are used and what assumptions do they make? This presentation will describe the derivation of pharmacokinetic parameters for both intravenous and extravascular dosing, first looking at a single dose and then extending to multiple dosing schedules. |
AdePro – A new Perspective on Safety Profiles
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG | The database in a clinical trial contains vast information on adverse events, involving hundreds of different adverse event terms with varying severity grades and different start and end dates. Despite this plethora of information, insight into the adverse events in a clinical study is usually limited to simple summary tables of absolute and relative numbers of adverse event occurrences. AdEPro – an innovation of Bayer’s Biostatistics Innovation Center – is an unparalleled approach to audio-visualize the safety profile of both the individual patient and of the entire study cohort, which enables every study team member to experience the study and emphasize with the patients. The AdEPro app depicts the temporal progress of all adverse events in every study subject and enables the user to give profound answers to complex questions surrounding adverse events such as the frequency, duration and correlation of adverse events of interest. |
Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes
| Nirav Ratia, GSK | Marginal structural models (MSMs) are casual models of dynamic treatment regimes (also known as treatment strategies or policies) designed to adjust for time-dependent confounding. These models are designed to adjust for exposures or treatment that vary over time, and standard approaches for adjustment of confounding can be biased when there exist time-dependent confounding. Dynamic treatment regimes (DTRs) provide the basis for statistical analysis in personalised medicine. A DTR is a decision rule that guides the treatment choices over the course of the therapy. The sequence of treatments a patient receives depends on the patient’s health status, response to prior treatment and other patient characteristics. |
Reading , RG2 6UU
The aim of this meeting is to provide a relaxed environment for career young statisticians
where they can present and discuss various statistical topics and interact/network with other statisticians in similar positions to themselves. The PSI conference and similar events can be daunting for some attendees both in terms of who is in the audience and also in being happy that what they present is deemed new and original. For this one day meeting the audience will be peers with similar levels of experience and will include content of interest to career young statisticians. In addition to presentations from fellow statisticians there will be a soft skills workshop on explaining statistics to non‐statisticians and ample opportunity to connect with colleagues across the industry.
CLICK HERE TO VIEW THE FLYER
Registration Costs:
| PSI Members | £25 + VAT |
| Non-Members | £95 + VAT |
The agenda for the meeting can be found below:
| 9.30 -9.55 | Registration |
| 9.55 – 10.00 | Welcome and Introduction |
| 10.00 – 11.00 | One label with different interpretations…Statistical lead, what does it really mean? |
|
| Charlotte Eden and Lucie Tesarova, QuintilesIMS |
| 11.00 – 11.20 | Break |
| 11.20 – 11.50 | Exploring recent developments in the MAMS methodology for designing an adaptive trial |
|
| Julia Abery, University of Reading |
| 11.50 – 12.20 | Seamless Study Designs & Real-time Data Capture Using Electronic Devices |
|
| Rhian Jacob, Roche |
| 12.20 – 13.20 | Lunch |
| 13.20 – 14:20 | Training session: Explaining statistics to non-statisticians |
|
| James Matcham, AstraZeneca / PSI Training Committee |
| 14.20 – 14.40 | Break |
| 14.40 – 15.10 | Introduction to Pharmacokinetics |
|
| Laura Cope, Quanticate |
| 15.10 – 15.40 | AdePro – A new Perspective on Safety Profiles |
|
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG |
| 15.40 – 16.00 | Break |
| 16.00 – 16.30 | Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes |
|
| Nirav Ratia, GSK |
| 16.30 | Close |
One label with different interpretations…Statistical lead, what does it really mean?
| Charlotte Eden and Lucie Tesarova, QuintilesIMS | Exploring the role of the Statistical lead from different perspectives. Focusing on life in a CRO to experiences in Pharma with audience participation to discuss how we work on some key factors throughout the life of a study. |
Exploring recent developments in the MAMS methodology for designing an adaptive trial
| Julia Abery, University of Reading | Multi-arm adaptive trials allow several new drugs to be assessed simultaneously, potentially giving improved efficiency over conventionally designed trials. In such a trial, data accumulating during the study are utilised to inform decisions about how the remainder of the trial should be conducted. Several different methodological approaches have been developed for multi-arm adaptive trials and a number of studies have compared the performance of different subsets of these proposed methods. The comparisons have not, however, considered the so-called MAMS approach, since methodology for the latter did not incorporate strong control of the family-wise error rate (FWER). Recently, the MAMS approach has been extended such that strong control of the FWER can be guaranteed. Furthermore, an automated process has been developed which can produce efficient designs for trials with any number of stages and treatment arms.Since MAMS is relatively easy to understand and implement, we set out to explore these developments and to compare MAMS to other well established methods.We show how MAMS compares favourably with the more established combination method for some scenarios and explore how use of a novel selection rule may offer a further option within MAMS methodology. |
Seamless Study Designs & Real-time Data Capture Using Electronic Devices
| Rhian Jacob, Roche | Developing a new drug in a highly competitive environment necessitates a fast to market approach. This talk looks at the ongoing '944' trial, a multiple cohort seamless phase II/III study. Key study endpoints are captured using electronic devices, providing high volume of data in real-time. This talk describes the opportunities and challenges for a statistician leading a phase II readout within a phase III framework, with discussion on novel data capture methods; is the industry ready to handle device data? |
Training session: Explaining statistics to non-statisticians
| James Matcham, AstraZeneca / PSI Training Committee |
|
Introduction to Pharmacokinetics
| Laura Cope, Quanticate | Pharmacokinetics is the study of the effect of the body on the drug. The pharmacokinetic profile maps the concentration of the drug in the body over time tracking how the drug is absorbed, distributed, metabolised and excreted by individuals. Drug concentration is linked to both efficacy and safety and hence pharmacokinetic studies form the basis of much earlier phase clinical trials. Pharmacokinetic profiles are often described using summary measures such as the area under the curve (AUC) and the maximum concentration (Cmax) but how are these parameters derived? What models are used and what assumptions do they make? This presentation will describe the derivation of pharmacokinetic parameters for both intravenous and extravascular dosing, first looking at a single dose and then extending to multiple dosing schedules. |
AdePro – A new Perspective on Safety Profiles
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG | The database in a clinical trial contains vast information on adverse events, involving hundreds of different adverse event terms with varying severity grades and different start and end dates. Despite this plethora of information, insight into the adverse events in a clinical study is usually limited to simple summary tables of absolute and relative numbers of adverse event occurrences. AdEPro – an innovation of Bayer’s Biostatistics Innovation Center – is an unparalleled approach to audio-visualize the safety profile of both the individual patient and of the entire study cohort, which enables every study team member to experience the study and emphasize with the patients. The AdEPro app depicts the temporal progress of all adverse events in every study subject and enables the user to give profound answers to complex questions surrounding adverse events such as the frequency, duration and correlation of adverse events of interest. |
Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes
| Nirav Ratia, GSK | Marginal structural models (MSMs) are casual models of dynamic treatment regimes (also known as treatment strategies or policies) designed to adjust for time-dependent confounding. These models are designed to adjust for exposures or treatment that vary over time, and standard approaches for adjustment of confounding can be biased when there exist time-dependent confounding. Dynamic treatment regimes (DTRs) provide the basis for statistical analysis in personalised medicine. A DTR is a decision rule that guides the treatment choices over the course of the therapy. The sequence of treatments a patient receives depends on the patient’s health status, response to prior treatment and other patient characteristics. |
Reading , RG2 6UU
The aim of this meeting is to provide a relaxed environment for career young statisticians
where they can present and discuss various statistical topics and interact/network with other statisticians in similar positions to themselves. The PSI conference and similar events can be daunting for some attendees both in terms of who is in the audience and also in being happy that what they present is deemed new and original. For this one day meeting the audience will be peers with similar levels of experience and will include content of interest to career young statisticians. In addition to presentations from fellow statisticians there will be a soft skills workshop on explaining statistics to non‐statisticians and ample opportunity to connect with colleagues across the industry.
CLICK HERE TO VIEW THE FLYER
Registration Costs:
| PSI Members | £25 + VAT |
| Non-Members | £95 + VAT |
The agenda for the meeting can be found below:
| 9.30 -9.55 | Registration |
| 9.55 – 10.00 | Welcome and Introduction |
| 10.00 – 11.00 | One label with different interpretations…Statistical lead, what does it really mean? |
|
| Charlotte Eden and Lucie Tesarova, QuintilesIMS |
| 11.00 – 11.20 | Break |
| 11.20 – 11.50 | Exploring recent developments in the MAMS methodology for designing an adaptive trial |
|
| Julia Abery, University of Reading |
| 11.50 – 12.20 | Seamless Study Designs & Real-time Data Capture Using Electronic Devices |
|
| Rhian Jacob, Roche |
| 12.20 – 13.20 | Lunch |
| 13.20 – 14:20 | Training session: Explaining statistics to non-statisticians |
|
| James Matcham, AstraZeneca / PSI Training Committee |
| 14.20 – 14.40 | Break |
| 14.40 – 15.10 | Introduction to Pharmacokinetics |
|
| Laura Cope, Quanticate |
| 15.10 – 15.40 | AdePro – A new Perspective on Safety Profiles |
|
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG |
| 15.40 – 16.00 | Break |
| 16.00 – 16.30 | Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes |
|
| Nirav Ratia, GSK |
| 16.30 | Close |
One label with different interpretations…Statistical lead, what does it really mean?
| Charlotte Eden and Lucie Tesarova, QuintilesIMS | Exploring the role of the Statistical lead from different perspectives. Focusing on life in a CRO to experiences in Pharma with audience participation to discuss how we work on some key factors throughout the life of a study. |
Exploring recent developments in the MAMS methodology for designing an adaptive trial
| Julia Abery, University of Reading | Multi-arm adaptive trials allow several new drugs to be assessed simultaneously, potentially giving improved efficiency over conventionally designed trials. In such a trial, data accumulating during the study are utilised to inform decisions about how the remainder of the trial should be conducted. Several different methodological approaches have been developed for multi-arm adaptive trials and a number of studies have compared the performance of different subsets of these proposed methods. The comparisons have not, however, considered the so-called MAMS approach, since methodology for the latter did not incorporate strong control of the family-wise error rate (FWER). Recently, the MAMS approach has been extended such that strong control of the FWER can be guaranteed. Furthermore, an automated process has been developed which can produce efficient designs for trials with any number of stages and treatment arms.Since MAMS is relatively easy to understand and implement, we set out to explore these developments and to compare MAMS to other well established methods.We show how MAMS compares favourably with the more established combination method for some scenarios and explore how use of a novel selection rule may offer a further option within MAMS methodology. |
Seamless Study Designs & Real-time Data Capture Using Electronic Devices
| Rhian Jacob, Roche | Developing a new drug in a highly competitive environment necessitates a fast to market approach. This talk looks at the ongoing '944' trial, a multiple cohort seamless phase II/III study. Key study endpoints are captured using electronic devices, providing high volume of data in real-time. This talk describes the opportunities and challenges for a statistician leading a phase II readout within a phase III framework, with discussion on novel data capture methods; is the industry ready to handle device data? |
Training session: Explaining statistics to non-statisticians
| James Matcham, AstraZeneca / PSI Training Committee |
|
Introduction to Pharmacokinetics
| Laura Cope, Quanticate | Pharmacokinetics is the study of the effect of the body on the drug. The pharmacokinetic profile maps the concentration of the drug in the body over time tracking how the drug is absorbed, distributed, metabolised and excreted by individuals. Drug concentration is linked to both efficacy and safety and hence pharmacokinetic studies form the basis of much earlier phase clinical trials. Pharmacokinetic profiles are often described using summary measures such as the area under the curve (AUC) and the maximum concentration (Cmax) but how are these parameters derived? What models are used and what assumptions do they make? This presentation will describe the derivation of pharmacokinetic parameters for both intravenous and extravascular dosing, first looking at a single dose and then extending to multiple dosing schedules. |
AdePro – A new Perspective on Safety Profiles
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG | The database in a clinical trial contains vast information on adverse events, involving hundreds of different adverse event terms with varying severity grades and different start and end dates. Despite this plethora of information, insight into the adverse events in a clinical study is usually limited to simple summary tables of absolute and relative numbers of adverse event occurrences. AdEPro – an innovation of Bayer’s Biostatistics Innovation Center – is an unparalleled approach to audio-visualize the safety profile of both the individual patient and of the entire study cohort, which enables every study team member to experience the study and emphasize with the patients. The AdEPro app depicts the temporal progress of all adverse events in every study subject and enables the user to give profound answers to complex questions surrounding adverse events such as the frequency, duration and correlation of adverse events of interest. |
Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes
| Nirav Ratia, GSK | Marginal structural models (MSMs) are casual models of dynamic treatment regimes (also known as treatment strategies or policies) designed to adjust for time-dependent confounding. These models are designed to adjust for exposures or treatment that vary over time, and standard approaches for adjustment of confounding can be biased when there exist time-dependent confounding. Dynamic treatment regimes (DTRs) provide the basis for statistical analysis in personalised medicine. A DTR is a decision rule that guides the treatment choices over the course of the therapy. The sequence of treatments a patient receives depends on the patient’s health status, response to prior treatment and other patient characteristics. |
Reading , RG2 6UU
The aim of this meeting is to provide a relaxed environment for career young statisticians
where they can present and discuss various statistical topics and interact/network with other statisticians in similar positions to themselves. The PSI conference and similar events can be daunting for some attendees both in terms of who is in the audience and also in being happy that what they present is deemed new and original. For this one day meeting the audience will be peers with similar levels of experience and will include content of interest to career young statisticians. In addition to presentations from fellow statisticians there will be a soft skills workshop on explaining statistics to non‐statisticians and ample opportunity to connect with colleagues across the industry.
CLICK HERE TO VIEW THE FLYER
Registration Costs:
| PSI Members | £25 + VAT |
| Non-Members | £95 + VAT |
The agenda for the meeting can be found below:
| 9.30 -9.55 | Registration |
| 9.55 – 10.00 | Welcome and Introduction |
| 10.00 – 11.00 | One label with different interpretations…Statistical lead, what does it really mean? |
|
| Charlotte Eden and Lucie Tesarova, QuintilesIMS |
| 11.00 – 11.20 | Break |
| 11.20 – 11.50 | Exploring recent developments in the MAMS methodology for designing an adaptive trial |
|
| Julia Abery, University of Reading |
| 11.50 – 12.20 | Seamless Study Designs & Real-time Data Capture Using Electronic Devices |
|
| Rhian Jacob, Roche |
| 12.20 – 13.20 | Lunch |
| 13.20 – 14:20 | Training session: Explaining statistics to non-statisticians |
|
| James Matcham, AstraZeneca / PSI Training Committee |
| 14.20 – 14.40 | Break |
| 14.40 – 15.10 | Introduction to Pharmacokinetics |
|
| Laura Cope, Quanticate |
| 15.10 – 15.40 | AdePro – A new Perspective on Safety Profiles |
|
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG |
| 15.40 – 16.00 | Break |
| 16.00 – 16.30 | Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes |
|
| Nirav Ratia, GSK |
| 16.30 | Close |
One label with different interpretations…Statistical lead, what does it really mean?
| Charlotte Eden and Lucie Tesarova, QuintilesIMS | Exploring the role of the Statistical lead from different perspectives. Focusing on life in a CRO to experiences in Pharma with audience participation to discuss how we work on some key factors throughout the life of a study. |
Exploring recent developments in the MAMS methodology for designing an adaptive trial
| Julia Abery, University of Reading | Multi-arm adaptive trials allow several new drugs to be assessed simultaneously, potentially giving improved efficiency over conventionally designed trials. In such a trial, data accumulating during the study are utilised to inform decisions about how the remainder of the trial should be conducted. Several different methodological approaches have been developed for multi-arm adaptive trials and a number of studies have compared the performance of different subsets of these proposed methods. The comparisons have not, however, considered the so-called MAMS approach, since methodology for the latter did not incorporate strong control of the family-wise error rate (FWER). Recently, the MAMS approach has been extended such that strong control of the FWER can be guaranteed. Furthermore, an automated process has been developed which can produce efficient designs for trials with any number of stages and treatment arms.Since MAMS is relatively easy to understand and implement, we set out to explore these developments and to compare MAMS to other well established methods.We show how MAMS compares favourably with the more established combination method for some scenarios and explore how use of a novel selection rule may offer a further option within MAMS methodology. |
Seamless Study Designs & Real-time Data Capture Using Electronic Devices
| Rhian Jacob, Roche | Developing a new drug in a highly competitive environment necessitates a fast to market approach. This talk looks at the ongoing '944' trial, a multiple cohort seamless phase II/III study. Key study endpoints are captured using electronic devices, providing high volume of data in real-time. This talk describes the opportunities and challenges for a statistician leading a phase II readout within a phase III framework, with discussion on novel data capture methods; is the industry ready to handle device data? |
Training session: Explaining statistics to non-statisticians
| James Matcham, AstraZeneca / PSI Training Committee |
|
Introduction to Pharmacokinetics
| Laura Cope, Quanticate | Pharmacokinetics is the study of the effect of the body on the drug. The pharmacokinetic profile maps the concentration of the drug in the body over time tracking how the drug is absorbed, distributed, metabolised and excreted by individuals. Drug concentration is linked to both efficacy and safety and hence pharmacokinetic studies form the basis of much earlier phase clinical trials. Pharmacokinetic profiles are often described using summary measures such as the area under the curve (AUC) and the maximum concentration (Cmax) but how are these parameters derived? What models are used and what assumptions do they make? This presentation will describe the derivation of pharmacokinetic parameters for both intravenous and extravascular dosing, first looking at a single dose and then extending to multiple dosing schedules. |
AdePro – A new Perspective on Safety Profiles
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG | The database in a clinical trial contains vast information on adverse events, involving hundreds of different adverse event terms with varying severity grades and different start and end dates. Despite this plethora of information, insight into the adverse events in a clinical study is usually limited to simple summary tables of absolute and relative numbers of adverse event occurrences. AdEPro – an innovation of Bayer’s Biostatistics Innovation Center – is an unparalleled approach to audio-visualize the safety profile of both the individual patient and of the entire study cohort, which enables every study team member to experience the study and emphasize with the patients. The AdEPro app depicts the temporal progress of all adverse events in every study subject and enables the user to give profound answers to complex questions surrounding adverse events such as the frequency, duration and correlation of adverse events of interest. |
Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes
| Nirav Ratia, GSK | Marginal structural models (MSMs) are casual models of dynamic treatment regimes (also known as treatment strategies or policies) designed to adjust for time-dependent confounding. These models are designed to adjust for exposures or treatment that vary over time, and standard approaches for adjustment of confounding can be biased when there exist time-dependent confounding. Dynamic treatment regimes (DTRs) provide the basis for statistical analysis in personalised medicine. A DTR is a decision rule that guides the treatment choices over the course of the therapy. The sequence of treatments a patient receives depends on the patient’s health status, response to prior treatment and other patient characteristics. |
Reading , RG2 6UU
The aim of this meeting is to provide a relaxed environment for career young statisticians
where they can present and discuss various statistical topics and interact/network with other statisticians in similar positions to themselves. The PSI conference and similar events can be daunting for some attendees both in terms of who is in the audience and also in being happy that what they present is deemed new and original. For this one day meeting the audience will be peers with similar levels of experience and will include content of interest to career young statisticians. In addition to presentations from fellow statisticians there will be a soft skills workshop on explaining statistics to non‐statisticians and ample opportunity to connect with colleagues across the industry.
CLICK HERE TO VIEW THE FLYER
Registration Costs:
| PSI Members | £25 + VAT |
| Non-Members | £95 + VAT |
The agenda for the meeting can be found below:
| 9.30 -9.55 | Registration |
| 9.55 – 10.00 | Welcome and Introduction |
| 10.00 – 11.00 | One label with different interpretations…Statistical lead, what does it really mean? |
|
| Charlotte Eden and Lucie Tesarova, QuintilesIMS |
| 11.00 – 11.20 | Break |
| 11.20 – 11.50 | Exploring recent developments in the MAMS methodology for designing an adaptive trial |
|
| Julia Abery, University of Reading |
| 11.50 – 12.20 | Seamless Study Designs & Real-time Data Capture Using Electronic Devices |
|
| Rhian Jacob, Roche |
| 12.20 – 13.20 | Lunch |
| 13.20 – 14:20 | Training session: Explaining statistics to non-statisticians |
|
| James Matcham, AstraZeneca / PSI Training Committee |
| 14.20 – 14.40 | Break |
| 14.40 – 15.10 | Introduction to Pharmacokinetics |
|
| Laura Cope, Quanticate |
| 15.10 – 15.40 | AdePro – A new Perspective on Safety Profiles |
|
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG |
| 15.40 – 16.00 | Break |
| 16.00 – 16.30 | Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes |
|
| Nirav Ratia, GSK |
| 16.30 | Close |
One label with different interpretations…Statistical lead, what does it really mean?
| Charlotte Eden and Lucie Tesarova, QuintilesIMS | Exploring the role of the Statistical lead from different perspectives. Focusing on life in a CRO to experiences in Pharma with audience participation to discuss how we work on some key factors throughout the life of a study. |
Exploring recent developments in the MAMS methodology for designing an adaptive trial
| Julia Abery, University of Reading | Multi-arm adaptive trials allow several new drugs to be assessed simultaneously, potentially giving improved efficiency over conventionally designed trials. In such a trial, data accumulating during the study are utilised to inform decisions about how the remainder of the trial should be conducted. Several different methodological approaches have been developed for multi-arm adaptive trials and a number of studies have compared the performance of different subsets of these proposed methods. The comparisons have not, however, considered the so-called MAMS approach, since methodology for the latter did not incorporate strong control of the family-wise error rate (FWER). Recently, the MAMS approach has been extended such that strong control of the FWER can be guaranteed. Furthermore, an automated process has been developed which can produce efficient designs for trials with any number of stages and treatment arms.Since MAMS is relatively easy to understand and implement, we set out to explore these developments and to compare MAMS to other well established methods.We show how MAMS compares favourably with the more established combination method for some scenarios and explore how use of a novel selection rule may offer a further option within MAMS methodology. |
Seamless Study Designs & Real-time Data Capture Using Electronic Devices
| Rhian Jacob, Roche | Developing a new drug in a highly competitive environment necessitates a fast to market approach. This talk looks at the ongoing '944' trial, a multiple cohort seamless phase II/III study. Key study endpoints are captured using electronic devices, providing high volume of data in real-time. This talk describes the opportunities and challenges for a statistician leading a phase II readout within a phase III framework, with discussion on novel data capture methods; is the industry ready to handle device data? |
Training session: Explaining statistics to non-statisticians
| James Matcham, AstraZeneca / PSI Training Committee |
|
Introduction to Pharmacokinetics
| Laura Cope, Quanticate | Pharmacokinetics is the study of the effect of the body on the drug. The pharmacokinetic profile maps the concentration of the drug in the body over time tracking how the drug is absorbed, distributed, metabolised and excreted by individuals. Drug concentration is linked to both efficacy and safety and hence pharmacokinetic studies form the basis of much earlier phase clinical trials. Pharmacokinetic profiles are often described using summary measures such as the area under the curve (AUC) and the maximum concentration (Cmax) but how are these parameters derived? What models are used and what assumptions do they make? This presentation will describe the derivation of pharmacokinetic parameters for both intravenous and extravascular dosing, first looking at a single dose and then extending to multiple dosing schedules. |
AdePro – A new Perspective on Safety Profiles
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG | The database in a clinical trial contains vast information on adverse events, involving hundreds of different adverse event terms with varying severity grades and different start and end dates. Despite this plethora of information, insight into the adverse events in a clinical study is usually limited to simple summary tables of absolute and relative numbers of adverse event occurrences. AdEPro – an innovation of Bayer’s Biostatistics Innovation Center – is an unparalleled approach to audio-visualize the safety profile of both the individual patient and of the entire study cohort, which enables every study team member to experience the study and emphasize with the patients. The AdEPro app depicts the temporal progress of all adverse events in every study subject and enables the user to give profound answers to complex questions surrounding adverse events such as the frequency, duration and correlation of adverse events of interest. |
Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes
| Nirav Ratia, GSK | Marginal structural models (MSMs) are casual models of dynamic treatment regimes (also known as treatment strategies or policies) designed to adjust for time-dependent confounding. These models are designed to adjust for exposures or treatment that vary over time, and standard approaches for adjustment of confounding can be biased when there exist time-dependent confounding. Dynamic treatment regimes (DTRs) provide the basis for statistical analysis in personalised medicine. A DTR is a decision rule that guides the treatment choices over the course of the therapy. The sequence of treatments a patient receives depends on the patient’s health status, response to prior treatment and other patient characteristics. |
Reading , RG2 6UU
The aim of this meeting is to provide a relaxed environment for career young statisticians
where they can present and discuss various statistical topics and interact/network with other statisticians in similar positions to themselves. The PSI conference and similar events can be daunting for some attendees both in terms of who is in the audience and also in being happy that what they present is deemed new and original. For this one day meeting the audience will be peers with similar levels of experience and will include content of interest to career young statisticians. In addition to presentations from fellow statisticians there will be a soft skills workshop on explaining statistics to non‐statisticians and ample opportunity to connect with colleagues across the industry.
CLICK HERE TO VIEW THE FLYER
Registration Costs:
| PSI Members | £25 + VAT |
| Non-Members | £95 + VAT |
The agenda for the meeting can be found below:
| 9.30 -9.55 | Registration |
| 9.55 – 10.00 | Welcome and Introduction |
| 10.00 – 11.00 | One label with different interpretations…Statistical lead, what does it really mean? |
|
| Charlotte Eden and Lucie Tesarova, QuintilesIMS |
| 11.00 – 11.20 | Break |
| 11.20 – 11.50 | Exploring recent developments in the MAMS methodology for designing an adaptive trial |
|
| Julia Abery, University of Reading |
| 11.50 – 12.20 | Seamless Study Designs & Real-time Data Capture Using Electronic Devices |
|
| Rhian Jacob, Roche |
| 12.20 – 13.20 | Lunch |
| 13.20 – 14:20 | Training session: Explaining statistics to non-statisticians |
|
| James Matcham, AstraZeneca / PSI Training Committee |
| 14.20 – 14.40 | Break |
| 14.40 – 15.10 | Introduction to Pharmacokinetics |
|
| Laura Cope, Quanticate |
| 15.10 – 15.40 | AdePro – A new Perspective on Safety Profiles |
|
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG |
| 15.40 – 16.00 | Break |
| 16.00 – 16.30 | Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes |
|
| Nirav Ratia, GSK |
| 16.30 | Close |
One label with different interpretations…Statistical lead, what does it really mean?
| Charlotte Eden and Lucie Tesarova, QuintilesIMS | Exploring the role of the Statistical lead from different perspectives. Focusing on life in a CRO to experiences in Pharma with audience participation to discuss how we work on some key factors throughout the life of a study. |
Exploring recent developments in the MAMS methodology for designing an adaptive trial
| Julia Abery, University of Reading | Multi-arm adaptive trials allow several new drugs to be assessed simultaneously, potentially giving improved efficiency over conventionally designed trials. In such a trial, data accumulating during the study are utilised to inform decisions about how the remainder of the trial should be conducted. Several different methodological approaches have been developed for multi-arm adaptive trials and a number of studies have compared the performance of different subsets of these proposed methods. The comparisons have not, however, considered the so-called MAMS approach, since methodology for the latter did not incorporate strong control of the family-wise error rate (FWER). Recently, the MAMS approach has been extended such that strong control of the FWER can be guaranteed. Furthermore, an automated process has been developed which can produce efficient designs for trials with any number of stages and treatment arms.Since MAMS is relatively easy to understand and implement, we set out to explore these developments and to compare MAMS to other well established methods.We show how MAMS compares favourably with the more established combination method for some scenarios and explore how use of a novel selection rule may offer a further option within MAMS methodology. |
Seamless Study Designs & Real-time Data Capture Using Electronic Devices
| Rhian Jacob, Roche | Developing a new drug in a highly competitive environment necessitates a fast to market approach. This talk looks at the ongoing '944' trial, a multiple cohort seamless phase II/III study. Key study endpoints are captured using electronic devices, providing high volume of data in real-time. This talk describes the opportunities and challenges for a statistician leading a phase II readout within a phase III framework, with discussion on novel data capture methods; is the industry ready to handle device data? |
Training session: Explaining statistics to non-statisticians
| James Matcham, AstraZeneca / PSI Training Committee |
|
Introduction to Pharmacokinetics
| Laura Cope, Quanticate | Pharmacokinetics is the study of the effect of the body on the drug. The pharmacokinetic profile maps the concentration of the drug in the body over time tracking how the drug is absorbed, distributed, metabolised and excreted by individuals. Drug concentration is linked to both efficacy and safety and hence pharmacokinetic studies form the basis of much earlier phase clinical trials. Pharmacokinetic profiles are often described using summary measures such as the area under the curve (AUC) and the maximum concentration (Cmax) but how are these parameters derived? What models are used and what assumptions do they make? This presentation will describe the derivation of pharmacokinetic parameters for both intravenous and extravascular dosing, first looking at a single dose and then extending to multiple dosing schedules. |
AdePro – A new Perspective on Safety Profiles
| Nicole Mentenich, Christoph Tasto and Bastian Becker, Bayer AG | The database in a clinical trial contains vast information on adverse events, involving hundreds of different adverse event terms with varying severity grades and different start and end dates. Despite this plethora of information, insight into the adverse events in a clinical study is usually limited to simple summary tables of absolute and relative numbers of adverse event occurrences. AdEPro – an innovation of Bayer’s Biostatistics Innovation Center – is an unparalleled approach to audio-visualize the safety profile of both the individual patient and of the entire study cohort, which enables every study team member to experience the study and emphasize with the patients. The AdEPro app depicts the temporal progress of all adverse events in every study subject and enables the user to give profound answers to complex questions surrounding adverse events such as the frequency, duration and correlation of adverse events of interest. |
Marginal and conditional structural mean models for optimising Dynamic Treatment Regimes
| Nirav Ratia, GSK | Marginal structural models (MSMs) are casual models of dynamic treatment regimes (also known as treatment strategies or policies) designed to adjust for time-dependent confounding. These models are designed to adjust for exposures or treatment that vary over time, and standard approaches for adjustment of confounding can be biased when there exist time-dependent confounding. Dynamic treatment regimes (DTRs) provide the basis for statistical analysis in personalised medicine. A DTR is a decision rule that guides the treatment choices over the course of the therapy. The sequence of treatments a patient receives depends on the patient’s health status, response to prior treatment and other patient characteristics. |
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Develop your non-technical skills by reading The Art of Explanation by Ros Atkins and joining the Sept-Dec 2025 book club. You will be invited to join facilitated discussions of the concepts and ideas and apply skills from the book in-between sessions.
Our monthly webinar will allow attendees to gain practical knowledge and skills in Open-Source coding and tools, with a focus on applications in the pharmaceutical industry. The sessions will provide starting points in a number of areas, correct any common misconceptions and provide valuable resources for further learning.
Date: Tuesday 9th September 2025 Join us to hear Sofia Weigle and Weng-Kee Wong present their recent work.
This course is aimed at biostatisticians with no or some pediatric drug development experience who are interested to further their understanding. We will give you an introduction to the pediatric drug development landscape. This will include identifying the key regulations and processes governing pediatric development, a discussion on the needs and challenges when conducting pediatric research and a focus on the ways to overcome these challenges from a statistical perspective.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
AI agents are large language models equipped with tools that can autonomously tackle challenging tasks. This talk will explore how generative AI agents can enable biomedical discovery.
The webinar is targeted at statisticians working in the pharmaceutical industry, and the objective is to 1) provide a basic understanding of IV methodology including how it relates to causal inference, and 2) present two inspirational pharma-relevant applications.
The morning will be dedicated to networking opportunities, helping attendees build connections with peers and professionals. In the afternoon, participants can attend a series of talks and/or workshops, including a career panel featuring speakers from both academia and industry, offering insights into various career paths. There will also be a statistical workshop and a potential poster session. To wrap up the day, we’re exploring interest in an informal after-work networking event for those keen to continue the conversation.
The Pre-Clinical Special Interest Group (SIG) Workshop 2025 will take place over two half-days on 7 - 8 October in Verona, Italy, bringing together experts from industry, academia, and regulatory institutions to discuss key challenges and innovations in pre-clinical research.
Four sessions will include ML foundation (including an introduction, data exploration for ML and dimensionality reduction and feature selection), Supervised learning (including support vector machines and model evaluation and interpretation), model optimization and unsupervised learning (including clustering) and advanced topics (including neural networks, deep learning and large language models).
The program will feature insightful sessions led by distinguished invited speakers, alongside a poster session showcasing the latest advancements in the field. Further details will be provided.
Date: Wednesday 5th November 2025 A careers talk about medical statistics and how it plays a crucial role in developing new medicines
Date: 19 November 2025 This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
As an Associate Director Biostatistics Early Development, you will be a key member of our biostatistics group, you will play a crucial role in the design, analysis, and interpretation of clinical trials for early development programs.
If you are passionate about biostatistics and real-world data, and are looking for an exciting opportunity to contribute to groundbreaking research, we encourage you to apply.
Are you passionate about making a difference in the world of healthcare? Novartis is seeking a dynamic and experienced professional to join our team in London at The Westworks.
As the Director of HTA Biostatistics & Medical Affairs, you will play a pivotal role in shaping the future of healthcare by providing strategic biostatistical leadership and expertise.
An exciting opportunity has arisen for a permanent Senior Medical Statistician & Statistical Programmer to join the UKCRC fully registered Derby Clinical Trials Support Unit (Derby CTSU).
As a Senior Principal Biostatistician, you will be responsible and accountable for all statistical work, both scientific and operational, for one or more assigned clinical trials
About cookies on this site
We use cookies to collect and analyse information on site performance and usage, to provide social media features and to enhance and customise content and advertisements.
About cookies on this site
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
CookieHub is a Consent Management Platform (CMP) which allows users to control storage and processing of personal information.
Cloudflare is a global network designed to make everything you connect to the Internet secure, private, fast, and reliable.
Microsoft Azure is a cloud computing platform offering a wide range of services, including virtual machines, databases, and AI tools.
AWS Elastic Load Balancing (ELB) automatically distributes incoming web traffic across multiple servers or services hosted on AWS.
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic.
Vimeo, Inc. is an American video hosting, sharing, services provider, and broadcaster. Vimeo focuses on the delivery of high-definition video across a range of devices.
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| ARRAffinity | .psiweb.org | Session | |
This cookie is set by websites run on the Windows Azure cloud platform. It is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session. | |||
| ARRAffinitySameSite | .psiweb.org | Session | |
Used to distribute traffic to the website on several servers in order to optimize response times. | |||
| __cf_bm | .vimeo.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| _cfuvid | .vimeo.com | Cloudflare, Inc. | Session |
Used by Cloudflare WAF to distinguish individual users who share the same IP address and apply rate limits | |||
| __cf_bm | .glueup.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| AWSALBTGCORS | psi.glueup.com | Amazon Web Services, Inc. | 7 days |
Used by Target Group-based load balancers for session stickiness. | |||
| AWSALBCORS | psi.glueup.com | Amazon Web Services, Inc. | 7 days |
Maintains session stickiness and secure routing between the user and backend servers through AWS load balancing. | |||
| PHPSESSID | psi.glueup.com | Session | |
Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages. | |||
| History.store | Session | ||
| cookiehub | .psiweb.org | CookieHub | 365 days |
Used by CookieHub to store information about whether visitors have given or declined the use of cookie categories used on the site. | |||
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| vuid | .vimeo.com | 400 days | |
These cookies are used by the Vimeo video player on websites. | |||
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| _ga_ | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics 4 to determine that two distinct hits belong to the same user across browsing sessions. | |||
| _ga | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics to determine that two distinct hits belong to the same user across browsing sessions. | |||
